We are live on
!
Find out more
TCS
Texas Children's Portfolio holdings
AUM
$20.5M
1-Year Est. Return
51.2%
This Fund
S&P 500
This Quarter
Est. Return
+14.68%
1 Year Est. Return
-51.2%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$82.2M
AUM Growth
+$10.5M
(+15%)
Cap. Flow
+$7.02M
Cap. Flow
% of AUM
8.54%
Top 10 Holdings %
Top 10 Hldgs %
87.85%
Holding
45
New
4
Increased
8
Reduced
9
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enterprise Products Partners
EPD
|
+$7.16M |
| 2 |
Solid Biosciences
SLDB
|
+$2.07M |
| 3 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$665K |
| 4 |
Iovance Biotherapeutics
IOVA
|
+$625K |
| 5 |
Wave Life Sciences
WVE
|
+$538K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
+$936K |
| 2 |
Acadia Pharmaceuticals
ACAD
|
+$796K |
| 3 |
Incyte
INCY
|
+$652K |
| 4 |
SAGE
Sage Therapeutics
SAGE
|
+$533K |
| 5 |
MRUS
Merus
MRUS
|
+$523K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 57.74% |
| 2 | Healthcare | 17.06% |
| 3 | Consumer Staples | 0% |
| 4 | Financials | 0% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Black Stone Minerals
BSM
$3.04B
| $40M | 48.66% |
2,268,592
| – | – |
|
2
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
$3.48B
| $14.8M | 18.04% |
120,651
| – | – |
|
|
3
Enterprise Products Partners
EPD
$82.2B
| $7.46M | 9.08% |
256,470
+256,189
| +91,170% | +$7.16M |
|
4
VanEck Oil Services ETF
OIH
$2.05B
| $2.34M | 2.84% |
6,779
| – | – |
|
|
5
Solid Biosciences
SLDB
$891M
| $1.29M | 1.57% |
9,382
+8,279
| +751% | +$2.07M |
|
|
6
Wave Life Sciences
WVE
$1.09B
| $1.19M | 1.44% |
30,546
+13,267
| +77% | +$538K |
|
7
United Therapeutics
UTHR
$22.5B
| $1.1M | 1.34% |
9,397
+3,711
| +65% | +$432K |
|
|
ONC
8
BeOne Medicines Ltd
ONC
$32.9B
| $1.1M | 1.33% |
8,306
+624
| +8% | +$84.2K |
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
| $999K | 1.21% |
7,389
-1,787
| -19% | -$222K |
|
|
ABMD
10
DELISTED
Abiomed Inc
ABMD
| $905K | 1.1% |
3,169
-477
| -13% | -$159K |
|
|
GHDX
11
DELISTED
Genomic Health, Inc.
GHDX
| $838K | 1.02% |
11,967
+3,932
| +49% | +$292K |
|
12
BioMarin Pharmaceuticals
BMRN
$11.6B
| $817K | 0.99% |
9,202
+155
| +2% | +$14.4K |
|
|
CCXI
13
DELISTED
ChemoCentryx, Inc.
CCXI
| $808K | 0.98% |
+58,142
| New | +$665K |
|
|
14
Incyte
INCY
$23.3B
| $785K | 0.95% |
9,125
-8,017
| -47% | -$652K |
|
|
SGEN
15
DELISTED
Seagen Inc. Common Stock
SGEN
| $774K | 0.94% |
10,566
-2,581
| -20% | -$184K |
|
16
Neurocrine Biosciences
NBIX
$17.2B
| $741K | 0.9% |
8,409
+1,971
| +31% | +$165K |
|
|
ZGNX
17
DELISTED
Zogenix, Inc.
ZGNX
| $739K | 0.9% |
13,429
-1,322
| -9% | -$62.9K |
|
|
18
Acadia Pharmaceuticals
ACAD
$4.39B
| $657K | 0.8% |
24,471
-34,075
| -58% | -$796K |
|
|
ARRY
19
DELISTED
Array Biopharma Inc
ARRY
| $621K | 0.76% |
25,485
-44,950
| -64% | -$936K |
|
|
FOLD
20
DELISTED
Amicus Therapeutics
FOLD
| $620K | 0.75% |
45,589
-11,953
| -21% | -$146K |
|
|
21
Iovance Biotherapeutics
IOVA
$2.08B
| $612K | 0.74% |
+64,348
| New | +$625K |
|
|
AMRN
22
Amarin Corp
AMRN
$297M
| $585K | 0.71% |
+1,410
| New | +$509K |
|
23
BioCryst Pharmaceuticals
BCRX
$2.31B
| $492K | 0.6% |
+60,479
| New | +$518K |
|
24
Apple
AAPL
$4.89T
| – | – |
-11,000
| Closed | -$434K |
|
25
AbbVie
ABBV
$449B
| – | – |
-476
| Closed | -$44K |
|
Similar funds
JJ
PCM
AF
C
BPI
IAM
SC
PCM
Texas Children's's Q1 2019 Portfolio in Review
As of Q1 2019, Texas Children's held 45 positions worth $82.2M, up 15% from $71.7M the previous quarter. Its ten largest holdings account for 88% of the portfolio.
Texas Children's deployed $7.02M of net new capital in Q1 2019, opening 4 new positions and adding to 8 existing holdings. Its largest new stake was ChemoCentryx, Inc.: 58,142 shares worth $808K.
By sector, the portfolio is most concentrated in Energy at 58% of assets, down from 58% a quarter earlier, followed by Healthcare and Consumer Staples.
On the sell side, the largest reduction was Array Biopharma Inc, an estimated $936K trimmed.
- Texas Children's's largest Q1 2019 buy was ChemoCentryx, Inc.: 58,142 shares worth $808K.
- Texas Children's added most to Enterprise Products Partners in Q1 2019, an estimated $7.16M increase.
- Texas Children's's biggest Q1 2019 reduction was Array Biopharma Inc, cutting an estimated $936K.
- Texas Children's fully exited Sage Therapeutics in Q1 2019, selling an estimated $533K.
- Texas Children's's ten largest holdings make up 88% of its $82.2M portfolio in Q1 2019.
- Texas Children's opened 4 new positions and closed 21 in Q1 2019.
- Texas Children's's portfolio value rose 15% quarter-over-quarter to $82.2M.
Based on Texas Children's's 13F filing for Q1 2019, filed 14 May 2019.